
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Characteristic	 HIV+	(n=1,025)	 HIV-	(n=379)	 HIV+	(n=277)	 HIV-	(n=101)	
	 N	 %	 N	 %	 N	 %	 N	 %	
Age	(years)																																 40-44	 133	 13.0	 54	 14.3	 31	 11.2	 26	 25.7	
45-49	 222	 21.7	 95	 25.1	 72	 26.0	 27	 26.7	
50-54	 289	 28.2	 87	 23.0	 71	 25.6	 16	 15.8	
55-59	 210	 20.5	 69	 18.2	 61	 22.0	 13	 12.9	
60-84	 171	 16.7	 74	 19.5	 42	 15.2	 19	 18.8	
Regiona	 Midwest	 164	 16.0	 62	 16.4	 74	 26.7	 38	 37.6	
Northeast	 328	 32.0	 113	 29.8	 80	 28.9	 19	 18.8	
South	 386	 37.7	 139	 36.7	 75	 27.1	 23	 22.8	
West	 147	 14.3	 65	 17.2	 48	 17.3	 21	 20.8	
Race/Ethnicity	 	 	 	 	 	 	 	 	
White	Non-Hispanic	 128	 12.5	 27	 7.1	 40	 14.4	 10	 9.9	
Black	Non-Hispanic	 761	 74.2	 294	 77.6	 209	 75.4	 77	 76.2	
Other	Non-Hispanic	 34	 3.3	 24	 6.3	 10	 3.6	 7	 6.9	
Hispanic	 102	 10.0	 34	 9.0	 18	 6.5	 7	 6.9	
Education					 <	High	School	 316	 30.9	 110	 29.0	 81	 29.4	 22	 21.8	
High	School	 334	 32.6	 115	 30.3	 91	 33.0	 28	 27.7	
>	High	School	 374	 36.5	 154	 40.6	 104	 37.7	 51	 50.5	
Unknown	 1	 	 0	 	 1	 	 0	 	
Annual	Household	Income	 ≤	$6,000	 137	 13.4	 78	 20.7	 37	 13.4	 24	 23.8	
$6,001-$12,000	 356	 34.8	 112	 29.8	 103	 37.2	 19	 18.8	
$12,001-$18,000	 145	 14.2	 48	 12.8	 31	 11.2	 12	 11.9	
$18,001-$24,000	 105	 10.3	 26	 6.9	 20	 7.2	 11	 10.9	
>	$24,000	 279	 27.3	 112	 29.8	 86	 31.1	 35	 34.7	
435	
	44	
Unknown	 3	 	 3	 	 0	 	 0	 	
Smoking	 Never	Smoker	 355	 34.6	 97	 25.6	 99	 35.7	 28	 27.7	
Former	Smoker	 278	 27.1	 105	 27.7	 65	 23.5	 32	 31.7	
Current	Smoker	 392	 38.2	 177	 46.7	 113	 40.8	 41	 40.6	
Alcohol	Use	(drinks/week)	 0	 589	 57.5	 170	 44.9	 148	 53.4	 48	 47.5	
0.1-7	 371	 36.2	 136	 35.9	 103	 37.2	 35	 34.7	
7.1-12	 24	 2.3	 29	 7.7	 6	 2.2	 3	 3.0	
	>	12	 41	 4.0	 44	 11.6	 20	 7.2	 15	 14.9	
Other	Substance	Useb	 Yes	 252	 24.6	 128	 33.8	 60	 21.7	 31	 30.7	
Active	Hepatitis	C	Infection	 RNA+	 96	 9.4	 21	 5.5	 33	 12.0	 5	 5.0	
	 Unknown	 2	 	 	 	 1	 	 	 	
HIV-specific	characteristics	 	 	 	 	 	 	
CD4	Count	(cells/mm3)c		 652	(441,	867)	 	 640	(436,	873)	 	
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One-Year	 	 	 	 	 	 	 	
Overall	 378	 25	 6.61	(4.11,	9.12)	 -	 	 -	 -	
HIV-	 101	 7	 		6.93	(1.98,	11.88)	 1.00	 0.00	 1.00	 0.00	


































































































































































































































































































	 N	 %	 N	 %	 N	 %	
Age	(years)a																																 53	(48-58)	 52	(48-59)	 53	(48-58)	
Regionb	 Midwest	 49	 21.9	 63	 41.2	 112	 29.7	
Northeast	 74	 33.0	 24	 15.7	 98	 26.0	
South	 64	 28.6	 34	 22.2	 98	 26.0	
West	 37	 16.5	 32	 20.9	 69	 18.3	
HIV	Status	 Negative	 60	 26.8	 41	 26.8	 101	 26.8	
Positive	 164	 73.2	 112	 73.2	 276	 73.2	
Race/Ethnicity		 Black	Non-Hispanic	 158	 70.5	 128	 83.7	 286	 75.9	
All	Other	Races	 66	 29.5	 25	 16.3	 91	 24.1	
Education					 <High	School	 46	 20.5	 57	 37.3	 103	 27.3	
High	School	 67	 29.9	 52	 34.0	 119	 31.6	
>High	School	 111	 49.6	 44	 28.8	 155	 41.1	
Annual	Household	Income	 ≤$12,000	 81	 36.2	 102	 66.7	 194	 51.5	
>$12,000	 143	 63.8	 51	 33.3	 183	 48.5	
Alcohol	Use	(drinks/week)	 ≤7	 205	 91.5	 126	 82.4	 331	 87.8	
>7	 19	 8.5	 27	 17.7	 46	 12.2	
















Crude	 	 	 -	
Non-smoker	 1.00	 0.00	 	
Smoker	 2.20	(1.01,	4.76)	 0.05	(0.00,	0.11)	 	
Fully-Adjusteda	 	 	 1.00	(0.46,	4.89)	
Non-smoker		 1.00	 0.00	 	
Smoker	 2.04	(0.85,	4.87)	 0.05	(-0.02,	0.11)	 	
Fully-Adjustedb	 	 	 1.02	(0.42,	11.08)	
Non-smoker		 1.00	 0.00	 	
Smoker	 1.61	(0.64,	4.03)	 0.03	(-0.03,	0.09)	 	
Fully-Adjustedc	 	 	 1.01	(0.43,	10.16)	
Non-smoker		 1.00	 0.00	 	



















	 	 	 	
	
Continuous	(5-unit	increment)	 25	 377	 1.15	(1.01,	1.31)	 0.01	(0.00,	0.03)	 -	
Quintiles	(1-unit	increment)	 25	 377	 1.29	(0.99,	1.67)	 0.01	(0.00,	0.03)	 -	
Crude	(Categorical)	 	 	 	 	 -	
≤7.5	 8	 226	 1.00	 0.00	 	
>7.5	 17	 151	 3.18	(1.41,	7.18)	 0.08	(0.02,	0.13)	 	
Fully-Adjusteda	 	 	 	 	 1.51	(0.45,	5.75)	
≤7.5	 8	 226	 1.00	 0.00	 	
>7.5	 17	 151	 2.86	(1.05,	7.78)	 0.09	(0.01,	0.17)	 	
Fully-Adjustedb	 	 	 	 	 1.57	(0.46,	7.38)	
≤7.5	 8	 226	 1.00	 0.00	 	
>7.5	 17	 151	 3.22	(1.17,	8.86)	 0.11	(0.02,	0.19)	 	
Fully-Adjustedc	 	 	 	 	 1.70	(0.47,	7.10)	
≤7.5	 8	 226	 1.00	 0.00	 	















	Model	 Cases	 N	 RR	(95%	CI)	 RD	(95%	CI)	
Mean	(Range)		
of	Stabilized	Weights	
Crude	(Linear)	 	 	 	 	 	
Continuous	(5-unit	increment)	 18	 276	 1.21	(1.03,	1.43)	 0.02	(0.00,	0.04)	 -	
Quintiles	(1-unit	increment)	 18	 276	 1.34	(0.99,	1.82)	 0.01	(0.00,	0.03)	 -	
Crude	(Categorical)	 	 	 	 	 -	
≤7.5	 6	 169	 1.00	 0.00	 	
>7.5	 12	 107	 3.16	(1.22,	8.16)	 0.08	(0.01,	0.14)	 	
Fully-Adjusteda	 	 	 	 	 1.54	(0.46,	6.64)	
≤7.5	 6	 169	 1.00	 0.00	 	
>7.5	 12	 107	 4.32	(1.39,	13.42)	 0.13	(0.02,	0.23)	 	
Fully-Adjustedb	 	 	 	 	 1.75	(043,	19.19)	
≤7.5	 6	 169	 1.00	 0.00	 	
>7.5	 12	 107	 4.90	(1.49,	16.08)	 0.15	(0.01,	0.29)	 	
Fully-Adjustedc	 	 	 	 	 1.84	(0.45,	11.43)	
≤7.5	 6	 169	 1.00	 0.00	 	















	Model	 Cases	 N	 RR	(95%	CI)	
RD	(95%	CI)	 Mean	(Range)		
of	Stabilized	Weights	
Crude	(Linear)	 	 	 	 	 	
Continuous	(5-unit	increment)	 25	 377	 1.15	(1.01,	1.30)	 0.01	(0.00,	0.03)	 -	
Quintiles	(1-unit	increment)	 25	 377	 1.26	(0.98,	1.64)	 0.01	(0.00,	0.03)	 -	
Crude	(Categorical)	 	 	 	 	 -	
≤7.5	 9	 226	 1.00	 0.00	 	
>7.5	 16	 151	 2.66	(1.21,	5.86)	 0.07	(0.01,	0.12)	 	
Fully-Adjusteda	 	 	 	 	 1.45	(0.47,	5.02)	
≤7.5	 9	 226	 1.00	 0.00	 	
>7.5	 16	 151	 2.90	(1.11,	7.55)	 0.09	(0.01,	0.17)	 	
Fully-Adjustedb	 	 	 	 	 1.53	(0.46,	8.08)	
≤7.5	 9	 226	 1.00	 0.00	 	
>7.5	 16	 151	 3.32	(1.25,	8.80)	 0.11	(0.02,	0.20)	 	
Fully-Adjustedc	 	 	 	 	 1.64	(0.48,	6.26)	
≤7.5	 9	 226	 1.00	 0.00	 	
>7.5	 16	 151	 2.80	(1.04,	7.56)	 0.09	(0.01,	0.17)	 	
Abbreviations:	RR,	Risk	Ratio;	CI,	Confidence	Interval;	RD,	Risk	Difference	
aWeighted	model	adjusts	for	age	(continuous),	education,	heavy	alcohol	use,	income,	race,	region		
bWeighted	model	adjusts	for	age	(continuous),	education,	heavy	alcohol	use,	income,	limited	recreational	drug	use	((injection	
drug	use,	or	use	of	heroin,	crack,	cocaine),	none),	race,	region		
cWeighted	model	adjusts	for	age	(continuous),	education,	heavy	alcohol	use,	income,	any	other	recreational	drug	use	(crack	
cocaine,	cocaine,	heroin,	methadone,	methamphetamines,	amphetamines,	marijuana,	prescription	drug	abuse,	or	other	
recreational	drug	use),	none),	race,	region	 	
6
6
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CHAPTER	6.	CONCLUSION	
	
SUMMARY	OF	FINDINGS	 	
This	project	sought	to	estimate	the	prevalence	and	one-year	risk	of	frailty,	and	
examine	the	effect	of	cigarette	smoking	on	the	one-year	risk	of	frailty	among	a	US	cohort	of	
women	with	and	at-risk	for	HIV	infection	who	were	at	least	40	years	of	age.	In	summary,	
we	demonstrated	that	the	prevalence	and	one-year	risk	of	frailty	among	women	in	their	
mid-fifties	with	and	at	risk	for	HIV	was	comparable	to	women	in	the	general	population	
who	are	at	least	65	years	of	age.	Our	findings	also	indicated	that	reported	exposure	to	
cigarette	smoking	increased	the	risk	for	frailty	among	women	with	and	at	risk	HIV	
infection.		
For	aim	one,	we	showed	that	the	prevalence	of	frailty	in	this	US	sample	of	women	
with	and	at	risk	for	HIV	was	11.5%	(10%	for	HIV+;	15%	for	HIV-).	After	validating	the	FFI,	
the	CHS	estimated	baseline	frailty	prevalence	among	adults	in	the	general	population	aged	
65	and	older	was	7%	among	women	and	5%	among	men[24].	Another	study	among	a	
representative	sample	of	Medicare	enrollees	aged	65	in	the	National	Health	and	Aging	
Trends	Study	estimated	frailty	prevalence	using	the	FFI	was	17%	among	women	and	13%	
among	men[31].	Lastly,	a	previous	analysis	in	the	WIHS	using	data	from	2005,	estimated	
frailty	prevalence	using	the	FFI	was	17%	among	women	with	HIV	and	10%	among	women	
at	risk	for	HIV[38].	However,	in	contrast	to	the	two	previous	studies	using	the	FFI,	we	chose
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to	use	the	cut	points	for	grip	strength	and	walking	speed	that	were	validated	in	the	general	
population	by	Fried,	rather	than	using	the	highest	and	lowest	quintiles	of	the	distributions	
from	our	HIV-seronegative	population[38]	or	the	population	distribution[31]	for	walking	
speed	and	grip	strength,	respectively.	This	approach	allowed	us	to	compare	the	
performance	on	frailty	measures	of	the	WIHS	population	to	the	CHS	population	of	women	
who	were	at	least	65	years	of	age	(11%	vs.	7%)[24].		
We	also	showed	that	the	prevalence	and	distribution	of	frailty	components	among	
the	frail,	pre-frail,	and	robust	were	comparable	for	women	with	and	at	risk	for	HIV.	The	
most	common	frailty	components	were	low	physical	activity	and	exhaustion,	which	the	
prevalence	among	frail	women	was	98%	and	88%,	respectively.	The	previous	study	among	
older	adults	in	Australia	receiving	rehabilitation	and	aged	care	services,	found	that	low	
physical	activity	and	exhaustion	were	also	the	most	common	frailty	components	at	65%	
and	63%[33].	We	also	determined	that	the	most	common	combinations	of	frailty	
components	for	both	pre-frail	and	frail	women	included	low	physical	activity	and	
exhaustion.		
For	aim	two,	the	one-year	risk	of	frailty	was	6.6%	(95%	CI:	4.1,	9.1),	and	risks	were	
similar	for	women	with	and	at	risk	for	HIV.	The	original	study	validating	the	FFI	in	the	CHS,	
estimated	that	the	four-year	risk	of	frailty	among	men	and	women	in	the	general	
population	aged	65	and	older	was	7%[24].	A	nationally	representative	sample	of	women	in	
the	general	population	aged	65-79	in	the	WHI-OS	reported	the	three-year	risk	of	frailty	was	
15%[25].	Many	risk	factors	that	were	associated	with	an	increased	three-year	risk	of	frailty	
in	the	WHI-OS	are	more	common	in	the	WIHS	cohort[25].	For	example,	the	prevalence	of	
women	with	an	annual	household	income	less	than	$20,000	was	14%,	and	these	women	
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were	2.0	times	as	likely	to	become	frail	over	a	three-year	period	compared	to	women	with	
an	annual	household	income	of	$75,000	or	more	(95%	CI:	1.6,	2.4)[25].	In	our	sample	
estimating	the	one-year	risk	of	frailty	among	women	with	and	at	risk	for	HIV,	55%	of	
women	had	an	annual	household	income	that	was	no	more	than	$18,000.		
For	aim	three,	we	revealed	that	reported	exposure	to	cigarette	smoking	was	
associated	with	an	increased	one-year	risk	of	frailty	among	women	with	and	at	risk	for	HIV.	
Though	the	sample	was	not	large	enough	to	detect	a	significant	difference,	current	smokers	
were	1.68	times	(95%	CI:	0.69,	4.06)	as	likely	to	become	frail	over	a	one-year	period	
compared	to	non-smokers,	adjusting	for	confounding	factors.	Also,	women	with	higher	
cumulative	exposure	to	smoking,	reflected	by	a	higher	number	of	smoking	pack-years	
(>7.5,	≤7.5),	demonstrated	an	increased	one-year	risk	for	frailty,	adjusting	for	confounding	
factors,	and	this	effect	appeared	to	be	more	apparent	among	women	with	HIV	(RR:	4.1;	
95%	CI:	1.2,	13.8).	The	recent	longitudinal	study	among	a	nationally	representative	sample	
of	2,542	adults	aged	60	and	older	in	England	found	that	current	smokers	were	1.60	times	
(95%	CI:	1.02,	2.51)	as	likely	to	develop	frailty	over	four	years	of	follow-up	compared	to	
non-smokers,	adjusting	for	other	factors[43].	In	our	study	population	of	women	in	their	mid-
fifties	with	and	at	risk	for	HIV	infection,	we	also	observed	a	similar	magnitude	of	effect	
comparing	smokers	to	non-smokers	over	a	one-year	period	after	adjustment	for	
confounding	factors.		
	
LIMITATIONS	
This	project	is	not	without	limitations.	Women	with	missing	data	for	performance-
based	measures	(grip	strength	and	walking	speed)	were	excluded	from	analyses.	We	did	
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seek	to	examine	the	assumption	that	these	missing	data	were	not	related	to	frailty,	HIV	
status,	or	smoking	status.	We	examined	the	distributions	of	the	other	three	frailty	
components	that	were	adequately	captured	for	women	at	least	40	years	old	during	the	
study	period.	We	found	that	the	distributions	for	HIV	status,	smoking	status,	and	the	other	
three	components	among	excluded	women	were	similar	to	those	of	women	included	in	our	
analyses.	We	also	found	the	distributions	for	current	smoking	exposure	and	frailty	for	
women	with	at	least	one	frailty	assessment	during	this	study	period	were	similar	to	the	
baseline	distributions	among	those	women	with	two	frailty	assessments.	We	also	assessed	
the	reasons	women	reported	for	not	wanting	to	participate	in	any	performance-based	
measurements.	Among	eligible	women	who	declined	to	complete	any	performance-based	
measurements	within	the	study	period	(n=126),	10%	explicitly	reported	reasons	related	to	
inability,	illness,	or	tiredness,	and	the	distribution	of	HIV	status	was	similar	to	those	
included	in	our	study.	
A	second	limitation	of	this	project	is	that	the	period	of	follow-up	was	relatively	
short.	Frailty	can	episodic	in	the	short-term,	but	without	intervention,	transitions	to	a	
higher	degree	of	frailty	are	more	common	and	complete	reversal	from	frailty	to	robustness	
is	rare	among	elderly	people[64].	It	is	worth	noting	that	it	is	possible	that	variability	in	the	
short-term	could	result	in	misclassification	of	the	outcome.	However,	there	is	no	evidence	
to	suggest	that	misclassification	of	frailty	is	likely	to	be	differential	with	regard	to	smoking	
exposure.	This	project	sought	to	assess	whether	smoking	exposure	could	produce	an	effect	
on	frailty	even	over	a	relatively	short	period	of	follow-up.	Given	the	limited	longitudinal	
data	in	frailty	research,	especially	among	people	with	HIV,	it	is	still	of	interest	to	examine	
the	effect	of	modifiable	risk	factors	on	the	short-term	risk	of	frailty	among	women	with	and	
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at	risk	for	HIV	that	can	help	guide	future	research.	Our	results	were	also	consistent	with	
limited	prospective	studies	in	the	general	population	reporting	current	cigarette	smoking	
as	a	risk	factor	for	frailty	over	longer	periods	of	follow-up[43].		
Also,	estimates	for	the	risk	ratios	and	risk	differences	for	frailty	were	imprecise.	
However,	estimates	for	frailty	prevalence	and	incidence	were	comparable	between	our	
population	and	the	general	population	of	women	at	least	65	years	of	age,	and	this	pattern	
should	be	further	examined.	We	also	observed	a	similar	magnitude	of	effect	in	our	analyses	
to	the	previous	longitudinal	study	in	the	general	population	comparing	the	four-year	risk	of	
frailty	for	current	smokers	and	non-smokers[43].	Our	results	were	also	robust	to	using	two	
separate	measures	of	exposure	to	smoking,	and	the	pattern	of	increased	frailty	risk	for	
higher	levels	of	reported	exposure	to	smoking	was	consistent.	Lastly,	though	identification	
of	potential	confounders	was	informed	by	a	DAG	and	final	selection	was	driven	by	a	
conditional	regression	model,	it	is	possible	that	unmeasured	confounding	could	help	
explain	our	results.	
	
IMPLICATIONS	AND	FUTURE	RESEARCH	
Several	characteristics	associated	with	frailty	in	the	general	population	are	more	
prevalent	among	people	with	HIV[13,	49].	In	addition	to	older	age	and	female	gender,	
minority	race/ethnicity,	lower	SES,	geographic	location,	comorbidities,	poor	nutrition,	
smoking,	and	possibly	alcohol	consumption	are	all	characteristics	associated	with	frailty	[24,	
31,	38,	39,	43].	As	mentioned	previously,	people	with	HIV	are	more	likely	to	smoke	(42%)	
compared	to	the	general	population	(21%)[49].	In	our	study	population,	many	of	these	aging	
risk	factors	were	highly	prevalent	among	women	with	HIV,	but	some	were	even	more	
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prevalent	among	women	at	risk	for	HIV.	Thus,	it	is	likely	that	the	high	burden	of	these	aging	
risk	factors	among	women	with	and	at	risk	for	HIV	contributed	to	the	high	prevalence	and	
risk	of	frailty	in	these	populations	relative	to	the	general	population.	Future	longitudinal	
studies	are	needed	to	pinpoint	modifiable	risk	factors	that	will	reduce	frailty	among	
populations	vulnerable	to	frailty	at	ages	younger	than	65.		
We	also	found	that	low	physical	activity	and	exhaustion	were	the	most	common	
frailty	components	and	most	commonly	occurred	in	conjunction	with	each	other	among	
frail	and	pre-frail	women	with	and	at	risk	for	HIV.	The	previous	study	among	older	adults	
in	Australia	receiving	rehabilitation	and	aged	care	services,	found	that	tailored	
interventions	targeting	identified	characteristics	of	frailty	reduced	frailty	and	improved	
mobility	over	a	12-month	period	compared	to	usual	care[33].	For	example,	one	of	the	
tailored	interventions	for	frail	adults	with	exhaustion	included	a	referral	to	a	psychiatrist.	
Previous	studies	also	demonstrate	that	resistance	exercise	training	increases	strength	in	
older	adults,	despite	age-associated	decreases	in	muscle	mass[34].	Given	that	studies	
suggest	frailty	is	associated	with	increased	healthcare	costs,	independent	of	socio-
demographics	and	comorbidity,	identifying	populations	that	could	most	benefit	from	
interventions	to	reduce	frailty	could	have	significant	public	health	impact[28].	With	regard	
to	frailty	prevention,	this	project	gives	weight	to	the	recent	body	of	literature	suggesting	
that	reported	cigarette	smoking	exposure	may	play	a	causal	role	in	the	development	of	
frailty.	This	project	also	suggests	that	the	intensity	and	duration	of	smoking	exposure	could	
play	a	more	pivotal	role	in	frailty	development,	rather	than	current	smoking	exposure	
alone.	Future	studies	are	needed	to	determine	the	long-term	impacts	of	various	levels	of	
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smoking	exposure	on	frailty	risk	and	smoking	interventions	to	reduce	frailty	risk	among	
women	with	and	without	HIV	infection.	
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